A pumpless multi-organ-on-a-chip (MOC) combined with a pharmacokinetic–pharmacodynamic (PK–PD) model

Biotechnology and Bioengineering

Volumn 114, Issue 2, 2017, Pages 432-443

  Lee, Hyuna ^a   Kim, Dae Shik ^b   Ha, Sang Keun ^c   Choi, Inwook ^c   Lee, Jong Min ^b   Sung, Jong Hwan ^a  

^a Hong Ik University   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Food Research Institute   (South Korea)

Author keywords

microfluidics; multi organ on a chip; PK PD modeling

Indexed keywords

CELL CULTURE; METABOLISM; MICROFLUIDICS; PHYSIOLOGY; TUMORS;

ANTICANCER ACTIVITIES; FLUIDIC CHANNELS; MATHEMATICAL FRAMEWORKS; MECHANISM OF ACTION; MULTI-ORGAN-ON-A-CHIP; P-D MODEL; PROOF OF CONCEPT; USER FRIENDLY;

DRUG INTERACTIONS;

DIOSMETIN; FIBRONECTIN; FLAVONOID; GLUCURONIDE; LUTEOLIN; XENOBIOTIC AGENT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL KILLING; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; FEMALE; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MICROELECTROMECHANICAL SYSTEM; MICROFLUIDICS; MULTI ORGAN ON A CHIP DEVICE; ORGAN; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; TREATMENT RESPONSE; BIOLOGICAL MODEL; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; DEVICES; DOSE RESPONSE; DRUG EFFECTS; EQUIPMENT DESIGN; HEP-G2 CELL LINE; MICROFLUIDIC ANALYSIS; PROCEDURES; TISSUE MICROARRAY;

ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT DESIGN; HELA CELLS; HEP G2 CELLS; HUMANS; LUTEOLIN; MICROFLUIDIC ANALYTICAL TECHNIQUES; MODELS, BIOLOGICAL; TISSUE ARRAY ANALYSIS;

EID: 84992560366     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.26087     Document Type: Article

References (72)

1. Allen JW, Khetani SR, Bhatia SN. 2005. In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol Sci 84(1):110–119.
2. Androutsopoulos VP, Spandidos DA. 2013. The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation. J Nutr Biochem 24(2):496–504.
3. Berthier E, Beebe DJ. 2007. Flow rate analysis of a surface tension driven passive micropump. Lab Chip 7(11):1475–1478.
4. Berthier E, Young EW, Beebe D. 2012. Engineers are from PDMS-land, biologists are from polystyrenia. Lab Chip 12(7):1224–1237.
5. Chapra SC, Canale RP. 2010. Numerical methods for engineers. Boston: McGraw-Hill Higher Education. xviii, p 968.
6. Chen B, Dong JQ, Pan WJ, Ruiz A. 2012a. Pharmacokinetics/pharmacodynamics model-supported early drug development. Curr Pharm Biotechnol 13(7):1360–1375.
7. Chen Z, Chen M, Pan H, Sun S, Li L, Zeng S, Jiang H. 2011. Role of catechol-O-methyltransferase in the disposition of luteolin in rats. Drug Metab Dispos 39(4):667–674.
8. Chen Z, Kong S, Song F, Li L, Jiang H. 2012b. Pharmacokinetic study of luteolin, apigenin, chrysoeriol and diosmetin after oral administration of Flos Chrysanthemi extract in rats. Fitoterapia 83(8):1616–1622.
9. Dickson M, Gagnon JP. 2004. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3(5):417–429.
10. Dingemanse J, Appel-Dingemanse S. 2007. Integrated pharmacokinetics and pharmacodynamics in drug development. Clin Pharmacokinet 46(9):713–737.
11. Dodds PS, Rothman DH, Weitz JS. 2001. Re-examination of the “3/4-law” of metabolism. J Theor Biol 209(1):9–27.
12. Esch MB, Mahler GJ, Stokol T, Shuler ML. 2014. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. Lab Chip 14(16):3081–3092.
13. Gradolatto A, Canivenc-Lavier MC, Basly JP, Siess MH, Teyssier C. 2004. Metabolism of apigenin by rat liver phase I and phase ii enzymes and by isolated perfused rat liver. Drug Metab Dispos 32(1):58–65.
14. Huh D, Torisawa YS, Hamilton GA, Kim HJ, Ingber DE. 2012. Microengineered physiological biomimicry: Organs-on-chips. Lab Chip 12(12):2156–2164.
15. Iori E, Vinci B, Murphy E, Marescotti MC, Avogaro A, Ahluwalia A. 2012. Glucose and fatty acid metabolism in a 3 tissue in-vitro model challenged with normo- and hyperglycaemia. PLoS ONE 7(4):e34704.
16. Kay SM. 1993. Fundamentals of statistical signal processing. Englewood Cliffs, N.J.: Prentice-Hall PTR.
17. Khetani SR, Berger DR, Ballinger KR, Davidson MD, Lin C, Ware BR. 2015. Microengineered liver tissues for drug testing. J Lab Autom 20(3):216–250.
18. Khetani SR, Bhatia SN. 2008. Microscale culture of human liver cells for drug development. Nat Biotechnol 26(1):120–126.
19. Kim J, Hegde M, Jayaraman A. 2010. Co-culture of epithelial cells and bacteria for investigating host-pathogen interactions. Lab Chip 10(1):43–50.
20. Kim S, Roy S. 2013. Microelectromechanical systems and nephrology: The next frontier in renal replacement technology. Adv Chronic Kidney Dis 20(6):516–535.
21. Kim SH, Lee JW, Choi I, Kim YC, Lee JB, Sung JH. 2013. A microfluidic device with 3-d hydrogel villi scaffold to simulate intestinal absorption. J Nanosci Nanotechnol 13(11):7220–7228.
22. Lee J, Razu ME, Wang X, Lacerda C, Kim JJ. 2015. Biomimetic cardiac microsystems for pathophysiological studies and drug screens. J Lab Autom 20(2):96–106.
23. Lindstedt SL. 1981. Body size, physiological time, and longevity of homeothermic animals. Quart Rev Biol 56(1):1–15.
24. Lopez-Lazaro M. 2009. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 9(1):31–59.
25. Mager DE, Wyska E, Jusko WJ. 2003. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31(5):510–518.
26. Marx U, Walles H, Hoffmann S, Lindner G, Horland R, Sonntag F, Klotzbach U, Sakharov D, Tonevitsky A, Lauster R. 2012. ‘Human-on-a-chip’ developments: A translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? Altern Lab Anim 40(5):235–257.
27. Maschmeyer I, Lorenz AK, Schimek K, Hasenberg T, Ramme AP, Hübner J, Lindner M, Drewell C, Bauer S, Thomas A, Sambo NS, Sonntag F, Lauster R, Marx U. 2015. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip 15(12):2688–2699.
28. Mersch-Sundermann V, Knasmuller S, Wu XJ, Darroudi F, Kassie F. 2004. Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents. Toxicology 198(1–3):329–340.
29. Meyvantsson I, Beebe DJ. 2008. Cell culture models in microfluidic systems. Annu Rev Anal Chem (Palo Alto Calif) 1:423–449.
30. Miller JS, Stevens KR, Yang MT, Baker BM, Nguyen DT, Cohen DM, Toro E, Chen AA, Galie PA, Yu X, Chaturvedi R, Bhatia SN, Chen CS. 2012. Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. Nat Mater 11(9):768–774.
31. Moraes C, Labuz JM, Leung BM, Inoue M, Chun TH, Takayama S. 2013. On being the right size: Scaling effects in designing a human-on-a-chip. Integr Biol (Camb) 5(9):1149–1161.
32. O'Leary KA, Day AJ, Needs PW, Mellon FA, O'Brien NM, Williamson G. 2003. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: The role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 65(3):479–491.
33. Oleaga C, Bernabini C, Smith AST, Srinivasan B, Jackson M, McLamb W, Platt V, Bridges R, Cai Y, Santhanam N, Berry B, Najjar S, Akanda N, Guo X, Martin C, Ekman G, Esch MB, Langer J, Ouedraogo G, Cotovio J, Breton L, Shuler ML, Hickman JJ. 2016. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep 6:20030.
34. Pamies D, Hartung T, Hogberg HT. 2014. Biological and medical applications of a brain-on-a-chip. Exp Biol Med (Maywood) 239(9):1096–1107.
35. Park JY, Kim SK, Woo DH, Lee EJ, Kim JH, Lee SH. 2009. Differentiation of neural progenitor cells in a microfluidic chip-generated cytokine gradient. Stem Cells 27(11):2646–2654.
36. Park SH, Ham S, Kwon TH, Kim MS, Lee DH, Kang JW, Oh SR, Yoon DY. 2014. Luteolin induces cell cycle arrest and apoptosis through extrinsic and intrinsic signaling pathways in MCF-7 breast cancer cells. J Environ Pathol Toxicol Oncol 33(3):219–231.
37. Primiceri E, Chiriaco MS, Rinaldi R, Maruccio G. 2013. Cell chips as new tools for cell biology-results, perspectives and opportunities. Lab Chip 13(19):3789–3802.
38. Prot JM, Aninat C, Griscom L, Razan F, Brochot C, Guillouzo CG, Legallais C, Corlu A, Leclerc E. 2011. Improvement of HepG2/C3a cell functions in a microfluidic biochip. Biotechnol Bioeng 108(7):1704–1715.
39. Sak K. 2014. Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacogn Rev 8(16):122–146.
40. Salehi-Nik N, Amoabediny G, Pouran B, Tabesh H, Shokrgozar MA, Haghighipour N, Khatibi N, Anisi F, Mottaghy K, Zandieh-Doulabi B. 2013. Engineering parameters in bioreactor's design: A critical aspect in tissue engineering. Biomed Res Int 2013:762132.
41. Sant S, Tao SL, Fisher OZ, Xu Q, Peppas NA, Khademhosseini A. 2012. Microfabrication technologies for oral drug delivery. Adv Drug Deliv Rev 64(6):496–507.
42. Shimoi K, Okada H, Furugori M, Goda T, Takase S, Suzuki M, Hara Y, Yamamoto H, Kinae N. 1998. Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett 438(3):220–224.
43. Shuler ML, Ghanem A, Quick D, Wong MC, Miller P. 1996. A self-regulating cell culture analog device to mimic animal and human toxicological responses. Biotechnol Bioeng 52(1):45–60.
44. Sin A, Chin KC, Jamil MF, Kostov Y, Rao G, Shuler ML. 2004. The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol Prog 20(1):338–345.
45. Spencer JP. 2003. Metabolism of tea flavonoids in the gastrointestinal tract. J Nutr 133(10):3255S–3261S.
46. Spencer JP, Abd-el-Mohsen MM, Rice-Evans C. 2004. Cellular uptake and metabolism of flavonoids and their metabolites: Implications for their bioactivity. Arch Biochem Biophys 423(1):148–161.
47. Spencer JP, Schroeter H, Crossthwaithe AJ, Kuhnle G, Williams RJ, Rice-Evans C. 2001. Contrasting influences of glucuronidation and O-methylation of epicatechin on hydrogen peroxide-induced cell death in neurons and fibroblasts. Free Radic Biol Med 31(9):1139–1146.
48. Stahl WR. 1965. Organ weights in primates and other mammals. Science 150(3699):1039–1042.
49. Sung JH, Dhiman A, Shuler ML. 2009. A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration. J Pharm Sci 98(5):1885–1904.
50. Sung JH, Esch MB, Prot JM, Long CJ, Smith A, Hickman JJ, Shuler ML. 2013. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip 13(7):1201–1212.
51. Sung JH, Esch MB, Shuler ML. 2010a. Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling. Expert Opin Drug Metab Toxicol 6(9):1063–1081.
52. Sung JH, Kam C, Shuler ML. 2010b. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10(4):446–455.
53. Sung JH, Shuler ML. 2009a. A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip 9(10):1385–1394.
54. Sung JH, Shuler ML. 2009b. Prevention of air bubble formation in a microfluidic perfusion cell culture system using a microscale bubble trap. Biomed Microdevices 11(4):731–738.
55. Sung JH, Shuler ML. 2012. Microtechnology for mimicking in vivo tissue environment. Ann Biomed Eng 40(6):1289–1300.
56. Sung JH, Srinivasan B, Esch MB, McLamb WT, Bernabini C, Shuler ML, Hickman JJ. 2014. Using physiologically-based pharmacokinetic-guided “body-on-a-chip” systems to predict mammalian response to drug and chemical exposure. Exp Biol Med (Maywood) 239(9):1225–1239.
57. Sung JH, Yu J, Luo D, Shuler ML, March JC. 2011. Microscale 3-D hydrogel scaffold for biomimetic gastrointestinal (GI) tract model. Lab Chip 11(3):389–392.
58. Tatosian DA, Shuler ML. 2009. A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers. Biotechnol Bioeng 103(1):187–198.
59. van ISC, Zegers MM, Kok JW, Hoekstra D. 1997. Segregation of glucosylceramide and sphingomyelin occurs in the apical to basolateral transcytotic route in HepG2 cells. J Cell Biol 137(2):347–357.
60. van Midwoud PM, Merema MT, Verpoorte E, Groothuis GM. 2010. A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. Lab Chip 10(20):2778–2786.
61. Vernetti LA, Senutovitch N, Boltz R, DeBiasio R, Ying Shun T, Gough A, Taylor DL. 2016. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med (Maywood) 241(1):101–114.
62. Vinci B, Murphy E, Iori E, Meduri F, Fattori S, Marescotti MC, Castagna M, Avogaro A, Ahluwalia A. 2012. An in vitro model of glucose and lipid metabolism in a multicompartmental bioreactor. Biotechnol J 7(1):117–126.
63. Viravaidya K, Shuler ML. 2004. Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnol Prog 20(2):590–597.
64. Vozzi F, Mazzei D, Vinci B, Vozzi G, Sbrana T, Ricotti L, Forgione N, Ahluwalia A. 2011. A flexible bioreactor system for constructing in vitro tissue and organ models. Biotechnol Bioeng 108(9):2129–2140.
65. Wagner I, Materne EM, Brincker S, Süßbier U, Frädrich C, Busek M, Sonntag F, Sakharov D, Trushkin E, Tonevitsky A, Lauster R, Marx U. 2013. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip 13(18):3538–3547.
66. Wang L, Sun B, Ziemer KS, Barabino GA, Carrier RL. 2010. Chemical and physical modifications to poly(dimethylsiloxane) surfaces affect adhesion of Caco-2 cells. J Biomed Mater Res A 93(4):1260–1271.
67. West GB, Brown JH. 2005. The origin of allometric scaling laws in biology from genomes to ecosystems: Towards a quantitative unifying theory of biological structure and organization. J Exp Biol 208(Pt 9):1575–1592.
68. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. Science 276(5309):122–126.
69. Wikswo JP, Curtis EL, Eagleton ZE, Evans BC, Kole A, Hofmeister LH, Matloff WJ. 2013. Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip 13(18):3496–3511.
70. Yang JH, Hsia TC, Kuo HM, Chao PD, Chou CC, Wei YH, Chung JG. 2006. Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metab Dispos 34(2):296–304.
71. Zhang H, Zhang M, Yu L, Zhao Y, He N, Yang X. 2012. Antitumor activities of quercetin and quercetin-5′, 8-disulfonate in human colon and breast cancer cell lines. Food Chem Toxicol 50(5):1589–1599.
72. Zheng Y, Chen J, Craven M, Choi NW, Totorica S, Diaz-Santana A, Kermani P, Hempstead B, Fischbach-Teschl C, López JA, Stroock AD. 2012. In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci U S A 109(24):9342–9347.